SCHEMBL23131561

SCHEMBL23131561

O=C(Cc1csc(NC(=O)C2CC2)n1)Nc1nc2ccccc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.62
▸ KMT2A Q03164 7/20 0.62
▸ RAB9A P51151 7/20 0.62
▸ NPC1 O15118 6/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ ALDH1A1 P00352 4/20 0.62
▸ NFKB1 P19838 2/20 0.62
▸ NFKB2 Q00653 2/20 0.62
▸ RELA Q04206 2/20 0.62
▸ HSD17B10 Q99714 2/20 0.62
▸ KDM4E B2RXH2 2/20 0.62
▸ POLB P06746 2/20 0.62
▸ TP53 P04637 2/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ CSNK1D P48730 3/20 0.57
▸ CYP1A2 P05177 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ LMNA P02545 2/20 0.56
▸ CHEK1 O14757 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23131562 0.85 DYRK1A (0.67) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL25720783 0.83 NPC1 (0.69) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL25721228 0.83 CSNK1D (0.53) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL880500 0.83 GAA (0.76) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL6227837 0.78 GAA (0.68) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL24101793 0.77 RAB9A (0.53) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL4909101 0.77 NPC1 (0.70) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23131445 0.77 NPC1 (0.62) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23131443 0.76 KDM4E (0.74) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL1148016 0.75 GAA (0.64) MEN1KMT2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230201339-A1 USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-06-29 — — US disclosed
US-20230201339-A1 USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-06-29 — — US disclosed
WO-2021055386-A1 USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201339-A1 USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE MYD88, IRF3, TLR1 MEN1 2516/4885KMT2A 4081/4885RAB9A 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback